- |||||||||| Clinical data, Journal, Machine learning: Machine learning-based integration develops a multiple programmed cell death signature for predicting the clinical outcome and drug sensitivity in colorectal cancer. (Pubmed Central) - Aug 12, 2024
In addition, the high-MPCDI group was more sensitive to AZD1332, Foretinib, and IGF1R_3801, and insensitive to AZD3759, AZD5438, AZD6482, Erlotinib, GSK591, IAP_5620, and Picolinici-acid, which suggests that the MPCDI can guide drug selection for CRC patients. As a new clinical classifier, the MPCDI can more accurately distinguish CRC patients who benefit from immunotherapy and develop personalized treatment strategies for CRC patients.
- |||||||||| TT001 / Ting Therap
Journal: Identification of a Novel Selective CDK9 Inhibitor for the Treatment of CRC: Design, Synthesis, and Biological Activity Evaluation. (Pubmed Central) - Mar 15, 2024
In this work, we preliminarily demonstrated the feasibility of CDK9 as a potent target of treatment for colorectal cancer, and a series of novel CDK9 inhibitors were rationally designed and synthesized based on the structure of AZD5438 (a pan CDKs inhibitor reported by AstraZeneca)...Research on the mechanism indicated that CLZX-205 could induce apoptosis in the HCT116 cell line by inhibiting phosphorylation of RNA polymerase II at Ser2, which resulted in the inhibition of apoptosis-related genes and proteins expression, and these results were validated at the cellular and tumor tissue levels. Currently, CLZX-205 is undergoing further research as a promising candidate for CRC treatment.
- |||||||||| TT001 / Ting Therap, Tafinlar (dabrafenib) / Novartis, BeiGene
Journal: Repurposing AZD5438 and Dabrafenib for Cisplatin-Induced Acute Kidney Injury. (Pubmed Central) - Jan 4, 2024
Currently, CLZX-205 is undergoing further research as a promising candidate for CRC treatment. Cisplatin-induced damage to the inner ear and kidneys share similar cellular beneficial responses to AZD5438 and dabrafenib highlighting the potential therapeutic use of these agents to treat both cisplatin-mediated kidney damage and hearing loss.
- |||||||||| Ibrance (palbociclib) / Pfizer, TT001 / Ting Therap
Journal: Design, synthesis, and biological evaluation of N-(pyridin-3-yl)pyrimidin-4-amine analogues as novel cyclin-dependent kinase 2 inhibitors for cancer therapy. (Pubmed Central) - Dec 14, 2023
Cisplatin-induced damage to the inner ear and kidneys share similar cellular beneficial responses to AZD5438 and dabrafenib highlighting the potential therapeutic use of these agents to treat both cisplatin-mediated kidney damage and hearing loss. Among them, the most promising compound 7l presented a broad antiproliferative efficacy toward diverse cancer cells MV4-11, HT-29, MCF-7, and HeLa with IC50 values of 0.83, 2.12, 3.12, and 8.61
- |||||||||| Journal, Gene Signature, IO biomarker: Identification of aneuploidy-related gene signature to predict survival in head and neck squamous cell carcinomas. (Pubmed Central) - Dec 7, 2023
Among them, the most promising compound 7l presented a broad antiproliferative efficacy toward diverse cancer cells MV4-11, HT-29, MCF-7, and HeLa with IC50 values of 0.83, 2.12, 3.12, and 8.61 We classified 3 molecular subtypes for HNSC patients and established an ARS prognostic model, which offered a prospective direction for prognosis in HNSC.
- |||||||||| TT001 / Ting Therap
Trial completion, Metastases: AZD5438 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed,
We classified 3 molecular subtypes for HNSC patients and established an ARS prognostic model, which offered a prospective direction for prognosis in HNSC. Recruiting --> Completed
|
